Japan human trial tests iPS cell treatment for Parkinson's

July 30, 2018
Japan's Riken research institute in Kyoto is a world leader in groundbreaking iPS cells

Japanese researchers on Monday announced the first human trial using a kind of stem cell to treat Parkinson's disease, building on earlier animal trials.

The research team at Kyoto University plans to inject five million induced Pluripotent Stem (iPS) cells—which have the potential to develop into any cell in the body—into patient brains, the university said in a press release.

The iPS cells from healthy donors will be developed into dopamine-producing brain cells, which are no longer present in people with Parkinson's disease.

Parkinson's disease is a chronic, that affects the body's motor system, often causing shaking and other difficulties in movement.

Worldwide, about 10 million people have the illness, according to the Parkinson's Disease Foundation.

Currently available therapies "improve symptoms without slowing or halting the disease progression," the foundation says.

But the new research aims to actively reverse the disease.

The clinical test with seven participants aged between 50 and 69 will begin on Wednesday.

The university will monitor the conditions of the patients for two years after the operation.

The human trial comes after an earlier trial involving monkeys.

Researchers announced last year that primates with Parkinson's symptoms regained significant mobility after iPS cells were inserted into their brains.

They also confirmed that the iPS cells had not transformed into tumors during the two years after the implant.

iPS cells are created by stimulating mature, already specialised, cells back into a juvenile state—basically cloning without the need for an embryo.

These can be derived from the patient, making them less likely to be rejected, while also sidestepping ethical qualms about taking cells from embryos.

The cells can be transformed into a range of different types of cells, and their use is a key sector of medical research.

In 2014, Riken, a Japanese government-backed research institution, carried out the world's first surgery to implant iPS cells to treat a patient with (AMD), a common medical condition that can lead to blindness in older people.

Osaka University is also planning a clinical test to treat heart failure by using a heart muscle cell sheet created from iPS cells.

In the US, scientists from Duke University said in January they had managed for the first time to grow functioning human muscle from iPS cells in the lab.

Explore further: Aggressive immune cells aggravate Parkinson's disease

Related Stories

Aggressive immune cells aggravate Parkinson's disease

July 20, 2018
Parkinson's disease, formerly referred to as "shaking palsy," is one of the most common disorders affecting movement and the nervous system. Medical researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) ...

A promising approach to translational research on stem cells for Parkinson's disease

July 23, 2018
A major factor underlying Parkinson's Disease (PD) pathology is the loss of dopamine neurons in the substantia nigra, and thus current therapies often aim to restore dopamine signaling. However, these treatments are not curative. ...

Stem cell implants boost monkeys with Parkinson's

February 22, 2012
Monkeys suffering from Parkinson's disease show a marked improvement when human embryonic stem cells are implanted in their brains, in what a Japanese researcher said Wednesday was a world first.

Dolly scientist backs research drive to tackle Parkinson's disease

April 11, 2018
Professor Sir Ian Wilmut – who led the team that created Dolly the sheep – has backed an initiative to tackle Parkinson's disease, after being diagnosed with the condition.

Stem cells reverse disease in a model of Parkinson's disease

May 16, 2011
In a new study to be published in the Journal of Clinical Investigation, researchers compared the ability of cells derived from different types of human stem cell to reverse disease in a rat model of Parkinson disease and ...

Monkeys with Parkinson's disease benefit from human stem cells

August 30, 2017
One of the last steps before treating patients with an experimental cell therapy for the brain is confirmation that the therapy works in monkeys. Today, scientists at the Center for iPS Cell Research and Application (CiRA), ...

Recommended for you

New transgenic model of Parkinson's illuminates disease biology

October 11, 2018
Parkinson's disease (PD) is a neurodegenerative disorder that presents clinically with abnormal movement and tremors at rest. In the brain, PD is marked by the accumulation of the protein, α-synuclein (αS), into clumps ...

Early Parkinson's patients waiting too long to seek medical evaluation

September 27, 2018
The time between diagnosis and the institution of symptomatic treatment is critical in the effort to find a cure for Parkinson's Disease (PD). A paper published in Nature Partner Journal: Parkinson's Disease notes too many ...

Molecule capable of halting and reverting neurodegeneration caused by Parkinson's disease identified

September 25, 2018
The small SynuClean-D molecule interrupts the formation of the alpha-synuclein amyloid fibres responsible for the onset of Parkinson's disease, and reverts the neurodegeneration caused by the disease. The study, headed by ...

Genomic dark matter activity connects Parkinson's and psychiatric diseases

September 20, 2018
Dopamine neurons are located in the midbrain, but their tendril-like axons can branch far into the higher cortical areas, influencing how we move and how we feel. New genetic evidence has revealed that these specialized cells ...

Gene therapy shown to remove core component of Parkinson's disease

September 14, 2018
An international team led by Rush researcher Jeffrey Kordower, Ph.D., has moved a step closer to developing a treatment to clear brain cells of a protein that is an integral cause of Parkinson's disease. The team published ...

ADHD may increase risk of Parkinson's disease and similar disorders

September 12, 2018
While about 11 percent of children (4-17 years old) nationwide have been diagnosed with attention-deficit hyperactivity disorder (ADHD), the long-term health effects of having ADHD and of common ADHD medications remains understudied. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.